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Abstract
Background:  A major portion of available fatty acids for adipocyte uptake is derived from
lipoprotein lipase (LPL)-mediated hydrolysis of circulating lipoprotein particles. In vivo studies
aimed at identifying the precise role of adipocyte-derived LPL in fat storage function of adipose
tissue have been unable to provide conclusive evidence due to compensatory mechanisms that
activate endogenous fatty acid synthesis. To address this gap in knowledge, we have measured the
effect of reducing adipocyte LPL expression on intracellular lipid accumulation using a well-
established cultured model of adipocyte differentiation.
Methods: siRNA specific for mouse LPL was transfected into 3T3-L1 adipocytes. Expression of
LPL was measured by quantitative real-time PCR and cell surface-associated LPL enzymatic activity
was measured by colorimetric detection following substrate (p-nitrophenyl butyrate) hydrolysis.
Apolipoprotein CII and CIII expression ratios were also measured by qRT-PCR. Intracellular lipid
accumulation was quantified by Nile Red staining.
Results: During differentiation of 3T3-L1 pre-adipocytes, LPL mRNA expression increases 6-fold
resulting in a 2-fold increase in cell surface-associated LPL enzymatic activity. Parallel to this
increase in LPL expression, we found that intracellular lipids increased ~10-fold demonstrating a
direct correlation between adipocyte-derived LPL expression and lipid storage. We next reduced
LPL expression in adipocytes using siRNA transfections to directly quantify the contributions of
adipocyte-derived LPL to lipid storage, This treatment reduced LPL mRNA expression and cell
surface-associated LPL enzymatic activity to ~50% of non-treated controls while intracellular lipid
levels were reduced by 80%. Exogenous addition of purified LPL (to restore extracellular lipolytic
activity) or palmitate (as a source of free fatty acids) to siRNA-treated cells restored intracellular
lipid levels to those measured for non-treated controls. We also found that adipocytes express
apolipoprotein CII and CIII and, in addition, the apoCII/apoCIII ratio remains largely unchanged in
cells with reduced LPL expression.
Conclusion: We provide evidence that adipocyte-derived LPL is required for efficient fatty acid
uptake and storage, and that adipocytes express their own source of apoCII and apoCIII for
regulating extracellular LPL activity. These findings demonstrate that adipocytes are capable of
producing the necessary enzymatic components and co-factors for efficient lipid storage
independent of vascular sources.
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Background
The adipocyte plays a crucial role in metabolic regulation,
serving as a storage depot for fatty acids and as an endo-
crine cell to manage energy utilization and feeding behav-
ior [1,2]. The mass of adipose tissue is maintained by a
well-controlled balance of cell proliferation (hyperplasia)
and increase in fat cell size (hypertrophy). Increases in
adipocyte hypertrophy result from the uptake and assimi-
lation of extracellular fatty acids into cytosolic triacylglyc-
erol-rich lipid droplets. The primary sources of these
extracellular fatty acids are those that are 1) associated
with circulating albumin or 2) hydrolyzed from triacylg-
lycerol-rich lipoprotein particles such as chylomicrons or
very low density lipoproteins (VLDL). Since chylomicrons
are short-lived fatty acid carriers present only during the
post-prandial period, it is accepted that VLDL particles
represent the major source of circulating fatty acids in the
form of triacylglycerols. Triacylglycerols are the major
component of VLDL and provide a concentrated source of
esterified fatty acids for peripheral tissues.
The availability of VLDL-derived fatty acids for energy
needs and adipocyte storage is dependent upon hydrolytic
activity of lipoprotein lipase (LPL) [3-6], and to a lesser
extent, endothelial lipase [7,8]. To date, two models have
been proposed describing how LPL mediates lipolysis of
circulating lipoproteins to release fatty acids for adipocyte
uptake [5]. In the first model, LPL originating in adipose
or muscle tissue is transported across the endothelial bar-
rier where it remains tethered to the lumenal surface
through its affinity for heparan sulfate proteoglycans
(HSPG). In this position, LPL can mediate release of fatty
acids from circulating lipoproteins for diffusion-based
transport to the adipocyte surface or newly released fatty
acids are transported through their association with circu-
lating albumin. Alternatively, largely intact lipoproteins
can cross the capillary endothelial barrier by either tran-
scytosis [9-11] or through leaky cell-cell junctions. Lipol-
ysis itself is known to cause capillary leakage and can
contribute to transendothelial transport [12,13].
Lipoprotein particles that are transported out of the vascu-
lature represent a significant source of fatty acids for adi-
pocyte storage. The release of fatty acids from these
particles is likely to be dependent on adipocyte-derived
LPL activity. One of our recent studies provides evidence
that HSPG found on the surface of adipocytes are essential
for lipid accumulation in adipocytes [14]. Although the
exact role played by these HSPG toward the uptake of fatty
acids remains to be identified; we have hypothesized that
HSPG serve as reaction centers for LPL-mediated triacylg-
lycerol hydrolysis. Cell surface HSPG are known to pro-
vide high affinity binding sites for both LPL [15,16] and
apoE-enriched lipoproteins [17-19]. In this manner,
HSPG can serve to co-localize enzyme and substrate, cre-
ating a focal reaction center to bring about the release of
fatty acids in proximity of the adipocyte cell surface.
Uptake of these liberated fatty acids can then be accom-
plished by fatty acid transport proteins, such as FAT/CD36
[20] or FATP1 [21], which are known to be expressed by
adipocytes [22-24]. A significant advantage of this mech-
anism is that lipoproteins, such as VLDL, can provide a
concentrated supply of fatty acids to adipocytes for uptake
as opposed to simply relying on free diffusion across the
endothelial barrier.
An essential element necessary for this mechanism to be
effective is adipocyte-derived LPL activity [25-27]. Studies
examining the effects of LPL gene ablation in mice have
attempted to define the role of adipocyte-derived LPL in
fat storage function of adipose tissue [28]. Homozygous
LPL deficiency was found to be lethal in mice; however,
muscle-specific expression of LPL in an LPL -/- back-
ground was able to rescue the lethal phenotype [29]. In
these crossbred mice, LPL expression is absent in adipose,
yet little or no change was noted in adipose tissue mass. It
was later shown that normal lipid storage was preserved in
these mice by an increase in endogenous fatty acid synthe-
sis [29]. Thus, interpreting the exact role of adipose-
derived LPL toward lipid storage in these studies was lim-
ited due to compensatory mechanisms that activate
endogenous fatty acid synthesis [29]. Because endog-
enous fatty acid synthesis in adipose is able to counterbal-
ance the loss of adipose-derived LPL activity in vivo,
animal studies have not been able to shed light on the
quantitative role played by this source of LPL in lipid
uptake and storage. In order to directly address this gap in
knowledge, we have measured the effect of reducing adi-
pocyte LPL expression on intracellular lipid accumulation
using a well-established cultured model of adipocyte dif-
ferentiation.
Methods
Cell culture and adipocyte differentiation
3T3-L1 cells were obtained from American Type Culture
Collection (Manassas, VA) and grown in Dulbecco's mod-
ified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA)
supplemented with 10% (v/v) fetal calf serum (Irvine Sci-
entific, Santa Ana, CA), 1 mM sodium pyruvate, 0.1 mM
non-essential amino acids, 2 mM L-glutamine, 100 μg/ml
streptomycin sulfate, and 100 units/ml penicillin. Cells
were cultured at 37°C with 10% CO2 and passaged twice
weekly. To differentiate 3T3-L1 cells into adipocytes, cells
were incubated with 250 nM dexamethasone, 450 μM 3-
isobutyl-1-methylxanthine, and 167 nM insulin for 2
days, followed by 167 nM insulin for an additional 3 days.
siRNA Transfection and PCR analysis
Purified Silencer®  pre-designed small interfering RNA
(siRNA) directed toward mouse lipoprotein lipase (LPL)Nutrition & Metabolism 2007, 4:22 http://www.nutritionandmetabolism.com/content/4/1/22
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was synthesized by Ambion Inc. (Austin, TX). The target
sequence for the siLPL is on exon 2, with a sense sequence
of GCAAAUUUGCCCUAAGGACtt and an antisense
sequence of GUCCUUAGGGCAAAUUUGCtt. Cells were
transfected with siRNA (100 nM) using DharmaFECT™ 3
transfection reagent according to the manufacturer's spe-
cific protocol for 3T3-L1 cells (Dharmacon, Inc., Lafayette,
CO). Total RNA was purified from cells using RNeasy
(Qiagen, Valencia, CA) and converted to cDNA using Taq-
Man Reverse Transcriptase (Applied Biosystems, Branch-
burg, NJ). LPL, leptin, apoCII, apoCIII, and β-actin
expression levels were measured by quantitative Real
Time PCR analysis (qRT-PCR) of cDNA samples. Primers
specific for LPL [GenBank:NM_008509] were designed to
amplify 231 base pairs flanking intron 4. Primer
sequences for LPL were: upstream, CTGCTGGCGTAG-
CAGGAAGT; downstream, GCTGGAAAGTGCCTC-
CATTG. Primers specific for leptin
[GenBank:NM_008493] were designed to amplify 213
base pairs flanking intron 2. Primer sequences for leptin
were: upstream, TGACACCAAAACCCTCATCA; down-
stream, TCATTGGCTATCTGCAGCAC. Primers specific for
apoCII [GenBank: NM_009695] were designed to amplify
147 base pairs flanking intron 2. Primer sequences for
apoCII were: upstream, GCAGGGCTCCCTCTTAAGTT;
downstream, AAAATGCCTGCGTAAGTGCT. Primers spe-
cific for apoCIII [GenBank: NM_023114] were designed
to amplify 99 base pairs flanking intron 3. Primer
sequences for apoCIII were: upstream, GGCTGGAT-
GGACAATCACTT; downstream, TGGTTGGTCCTCAG-
GGTTAG. Primers specific for β-actin
[GenBank:NM_007393] were designed to amplify 287
base pairs flanking intron 3. Primer sequences for β-actin
were: upstream, CCTGAACCCTAAGGCCAACC; down-
stream, CAGCTGTGGTGGTGAAGCTG. qRT-PCR was per-
formed using ABsolute QPCR SYBR Green Mix (Fisher
Scientific, Atlanta, GA) with the following cycling param-
eters: 1 cycle, 95°C, 15 min; 40 cycles, 95°C, 15 sec,
60°C, 1 min. β-actin mRNA levels were measured in par-
allel with identical cycling conditions and used to normal-
ize values obtained for LPL, leptin, apoCII, and apoCIII
expression. Relative quantitation was performed using the
comparative CT method. For this analysis, the amount of
target message (LPL, leptin, apoCII, or apoCIII in siRNA-
treated adipocytes) was normalized to the internal refer-
ence (β-actin) and compared to the calibrator (LPL, leptin,
apoCII, or apoCIII in untreated adipocytes).
For straight RT-PCR reactions of leptin, apoCII, apoCIII
and  β-actin, isolated mRNA was reverse transcribed as
described above and cDNA amplification was performed
using TaKaRa Ex Taq™ (Fisher Scientific, Atlanta, GA) with
the following cycling parameters: 1 cycle, 95°C, 2 min; 40
cycles, 95°C, 30 sec, 60°C, 30 sec, 72 °C 1 min. Amplified
products were separated on 3% agarose gels and stained
with Gel Star® (Cambrex, Rockland, ME).
LPL enzymatic activity
Cells, grown in 6-well plates, were rinsed twice with phos-
phate buffered saline, pH 7 (PBS), and incubated with
200 μg/ml heparin (from porcine intestinal mucosa, 180
USP units/mg, Sigma, St. Louis, MO) prepared in PBS for
15 min at 25°C. Following incubation, the heparin solu-
tion was centrifuged (15,000 × g, 5 min, 4°C) to remove
cell debris and mixed with an equal volume of 2 mM p-
nitrophenyl butyrate (PNPB). Absorbance at 405 nm was
recorded following a 10 min incubation using a Genesys
UV Spectrophotometer. LPL activity is reported as the
amount of p-nitrophenol product formed over the 10 min
incubation. The molar extinction coefficient of p-nitroph-
enol at 405 nm is 11,000 M-1cm-1.
Palmitate-albumin complexes
Palmitate (sodium salt), purified bovine LPL, and fatty
acid-free albumin were purchased from Sigma. Palmitate-
albumin complexes were prepared as follows. Palmitate
was dissolved in 3% albumin (wt/v) to a final concentra-
tion of 10 mM in 1X Hank's Balanced Salt Solution. The
mixture was slowly heated to 50°C and stirred overnight.
The mixture was then cooled to 37°C, stirred for an addi-
tional 3 hours and sterile filtered through a 0.2 μm syringe
filter. Protein was quantified using the BCA™ Protein
Assay Kit (Pierce, Rockford, IL).
Nile Red staining and quantitation
Cells were rinsed twice with PBS, pH 7, and trypsinized
with phenol red-free 0.05% Trypsin-EDTA (Invitrogen
Corporation, Grand Island, NY) for 5 min at 37°C. Cells
were fixed in suspension with 0.5% paraformaldehyde (v/
v) in PBS for 10 min at 25°C. A stock solution of 1 mg/ml
Nile Red (Sigma, St. Louis, MO) was prepared in acetone
and added to the cell preparation to a final concentration
of 5 μg/ml. Cells were incubated at 25°C for 30 min in the
dark. Flow cytometry was performed using a FACScan
flow cytometer (λexcitation 488 nm; λemission 585 nm). Nile
Red fluorescence was quantitated using a Shimadzu RF-
1501 spectrofluorophotometer (λexcitation 488 nm; λemission
560 nm).
Statistical analysis
All experimental protocols were done in triplicate. All
error bars represent standard deviation of triplicate points.
Results
LPL expression and cell-surface enzymatic activity of 3T3-
L1 preadipocytes and differentiated adipocytes
Although it is known that adipocytes synthesize LPL in
vivo, identifying the quantitative changes in LPL transcrip-
tion during adipocyte differentiation have only been par-Nutrition & Metabolism 2007, 4:22 http://www.nutritionandmetabolism.com/content/4/1/22
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tially examined [30] and no information is available as to
the relationship between changes in LPL mRNA levels and
LPL enzymatic activities. To examine this relationship, we
induced differentiation in 3T3-L1 mouse pre-adipocytes
with a standard cocktail of dexamethasone, 3-isobutyl-1-
methylxanthine, and insulin, and measured LPL transcrip-
tional changes by quantitative qRT-PCR and LPL enzy-
matic activity by a colorimetric assay. Upon
differentiation, LPL mRNA levels increased approximately
6-fold, which is in close agreement with prior measure-
ments [26] (Fig. 1A). To measure cell surface-associated
LPL enzymatic levels, cells were incubated with heparin to
release HSPG-bound LPL and this material was incubated
with lipase-specific substrate p-nitrophenyl butyrate. We
found that LPL enzymatic levels increased 2-fold follow-
ing adipocyte differentiation (Fig. 1B). Full differentiation
of these cells was confirmed by activation of leptin expres-
sion (Fig. 1A, inset). We also stained differentiated adi-
pocytes in parallel with the fluorescent lipophilic dye,
Nile Red, and quantitated increases in intracellular lipid
storage by flow cytometry (Fig. 2). Intracellular lipids
increased by ~10-fold demonstrating a direct correlation
between LPL expression and lipid storage.
LPL expression by adipocytes is necessary for intracellular 
lipid accumulation
As described above, attempts to measure the contribu-
tions of LPL to lipid storage in adipocytes in vivo have
been met with difficulty due to activation of endogenous
fatty acid synthesis. This activation is largely due to hor-
monal regulation of adipocyte physiology [3] and also to
what has been attributed to an organismic survival func-
tion [29,31]. Therefore, the most straightforward
approach to determine if adipocyte-derived LPL directly
contributes to lipid uptake and storage is to examine the
affects of inhibiting LPL expression on lipid accumulation
using cultured adipocytes. Quantifying intracellular lipid
accumulation is easily accomplished by measuring incor-
poration of Nile Red by fluorometry as shown in Fig. 2. In
order to obtain measurable Nile Red fluorescence, pre-
adipocytes must be allowed to take up and store lipids for
the full 5 days of differentiation. We chose to use siRNA
methodologies to inhibit LPL expression; however,
because the transfection process might adversely affect
critical events during differentiation, we chose to perform
our siRNA transfections prior to initiating adipocyte
induction. For this approach to work, our siRNA treat-
ment would have to inhibit LPL expression for a mini-
mum of 5 days rather than the typical 24–48 hour period
in order to accommodate the minimum time necessary
for full differentiation. To determine if siRNA treatment
will be able to sufficiently inhibit LPL expression for 5
days following transfections, we performed a time course
study measuring LPL expression by qRT-PCR during the
entire course of differentiation. 3T3-L1 pre-adipocytes
were transfected with LPL specific siRNA, allowed to
recover for the prescribed 3 h, and incubated with adi-
pocyte induction reagents. At 24 h intervals up to 5 days,
total RNA was extracted from cells and subjected to qRT-
PCR analysis to measure siRNA-mediated inhibition of
LPL expression. Twenty four hours post-transfection, we
found LPL mRNA expression inhibited by 80% (Fig. 3).
LPL expression showed a steady recovery after each subse-
quent 24 hour period; yet by day 5, our endpoint for
LPL gene expression and enzymatic levels increase following  differentiation of pre-adipocytes Figure 1
LPL gene expression and enzymatic levels increase 
following differentiation of pre-adipocytes. 3T3-L1 
cells were treated with or without adipocyte induction rea-
gents as described in Methods. (A) Total RNA was extracted 
from cells and LPL mRNA levels were measured by qRT-PCR 
using the Comparative CT method. Inset, specific amplifica-
tion of leptin sequence (213 bp) was done by straight reverse 
transcriptase-PCR to confirm differentiation of pre-adi-
pocytes. Amplification of β-actin sequence (287 bp) was per-
formed as a loading control. (B) Cells were incubated with 
heparin (200 μg/ml) to release surface associated LPL. The 
heparin releasable fraction was then incubated with p-nitro-
phenyl butyrate (1 mM final concentration) for 10 min and 
absorbance was measured at 405 nm.Nutrition & Metabolism 2007, 4:22 http://www.nutritionandmetabolism.com/content/4/1/22
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quantitating lipid accumulation, LPL expression was still
inhibited by ~40%.
Based on these findings we predicted that the level of inhi-
bition measured after 5 days would be sufficient to deter-
mine if endogenously synthesized LPL contributed to
lipid accumulation in our cultured adipocyte model. We
transfected 3T3-L1 pre-adipocytes with LPL-specific
siRNA, induced adipocyte differentiation for 5 days, and
then examined 1) LPL mRNA expression changes due to
siRNA treatment, 2) the resulting affect on cell surface LPL
activity levels, and 3) performed a quantitative evaluation
of intracellular lipid accumulation (Fig. 4). Similar to the
results we obtained for Fig. 3, siRNA treatment reduced
LPL mRNA expression to ~50% of non-treated controls
after the 5 day adipocyte induction period (Fig. 4A).
Importantly, siRNA treatment showed no effect on adi-
pocyte differentiation as no measurable change was found
for leptin expression when comparing siRNA treated ver-
sus non-treated cells (Fig. 4A). Cell surface associated,
heparin-releasable LPL enzymatic activity was also
reduced by ~50% in siRNA treated cells (Fig. 4B). Most
importantly, Nile Red staining of siRNA treated adi-
pocytes was reduced by 80% compared with non-treated
cells (Fig. 4C).
Exogenous addition of LPL or palmitate restores 
intracellular fat storage in siRNA treated adipocytes
Since siRNA-mediated inhibition of LPL in adipocytes sig-
nificantly reduced intracellular lipid storage, we reasoned
that the exogenous addition of purified LPL (to restore
extracellular lipase activity lost due to siRNA treatment) or
palmitate (to supply cells with a source of available free
fatty acid thus abrogating the need for LPL hydrolysis
activity) would be expected to reverse the phenotype seen
in siRNA treated cells. To establish control values, adi-
pocytes were treated with or without siRNA for LPL and
intracellular lipid accumulation was quantified by Nile
Red staining as was done in Figure 4C. In parallel, siRNA-
treated adipocytes were also incubated with either puri-
fied LPL or palmitate which was pre-bound to albumin to
serve as a soluble fatty acid carrier. As shown in Figure 5,
both of these additions were independently able to
reverse the effects of reducing LPL expression by restoring
intracellular lipid to levels obtained in non-siRNA-treated
cells. These results complement the data acquired from
simple siRNA treatment and provide additional evidence
siRNA-mediated reduction in LPL expression over a 5 day  adipocyte differentiation period Figure 3
siRNA-mediated reduction in LPL expression over a 
5 day adipocyte differentiation period. 3T3-L1 cells 
were transfected with siRNA specific for LPL, followed by 
incubation with adipocyte induction reagents. After each 24 h 
period up to day 5 post-induction, total RNA was isolated 
from adipocytes and LPL expression was assessed by qRT-
PCR. Results were analyzed by the Comparative CT method 
with fully differentiated, non-treated adipocytes representing 
100% LPL expression. β-actin expression was amplified in 
parallel and used to normalize replicate points.
Intracellular lipid accumulation during differentiation of pre- adipocytes correlates with increased LPL expression Figure 2
Intracellular lipid accumulation during differentiation 
of pre-adipocytes correlates with increased LPL 
expression. 3T3-L1 cells, treated with or without adipocyte 
induction reagents, were incubated with Nile Red (5 μg/ml). 
Lipid associated Nile Red was then viewed by fluorescence 
microscopy (630X) and quantified by flow cytometry.Nutrition & Metabolism 2007, 4:22 http://www.nutritionandmetabolism.com/content/4/1/22
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that adipocyte-derived LPL activity is essential to generate
available fatty acids for uptake and storage.
ApoCII and apoCIII expression in adipocytes
ApoCII and apoCIII are known to be, respectively, a
strong activator and strong inhibitor of LPL [32,33].
Within the vasculature, apoCII and apoCIII are readily
available to regulate LPL activity since they are found asso-
ciated with circulating lipoprotein particles [34,35].
Although the primary in vivo site for synthesis of apoCII
and apoCIII is the liver [36], we questioned if adipocytes
are also able to synthesize their own source of apoCII and
apoCIII which would provide these extravascular cells the
means to regulate LPL activity independent of circulating
apoCII and apoCIII. To date, expression of these LPL reg-
ulators by adipocytes has not been examined. To address
this question, we first performed RT-PCR analysis on
cDNA samples generated from differentiated 3T3-L1 adi-
pocyte RNA. As shown in Figure 6A, cultured adipocytes
do in fact express both apoCII and apoCIII.
Since apoCII and apoCIII have opposite effects on LPL
activity, it is generally accepted that the state of LPL activ-
Exogenous addition of LPL or palmitate reverses the effect of  LPL-siRNA treatment on lipid accumulation by adipocytes Figure 5
Exogenous addition of LPL or palmitate reverses the 
effect of LPL-siRNA treatment on lipid accumulation 
by adipocytes. 3T3-L1 cells were transfected with or with-
out LPL-specific siRNA (100 nM), followed by incubation 
with adipocyte induction reagents. In parallel, some cells 
were also incubated with palmitate-albumin (2 mg/ml pro-
tein) beginning with the second addition of insulin during the 
differentiation protocol. Alternatively, LPL (6.67 Units/ml) 
was added with the second addition of insulin and each suc-
cessive day until measuring intracellular lipid levels. After a 
total of five days, intracellular lipid accumulation was quanti-
fied by measuring cell-associated Nile Red using fluorometry.
Inhibition of LPL gene expression in adipocytes causes a cor- responding reduction in cell surface, HSPG-associated LPL  activity and intracellular lipid accumulation Figure 4
Inhibition of LPL gene expression in adipocytes 
causes a corresponding reduction in cell surface, 
HSPG-associated LPL activity and intracellular lipid 
accumulation. 3T3-L1 cells were transfected with LPL-spe-
cific siRNA, followed by incubation with adipocyte induction 
reagents for 5 days. (A) Total RNA was isolated from cells 
and subjected to qRT-PCR analysis to determine relative LPL 
and leptin mRNA expression levels in siRNA treated and 
non-treated control cells. (B) Heparin-releasable LPL enzy-
matic activity was measured in siRNA treated and non-
treated control cells as described in Fig. 1. (C) Intracellular 
lipid droplet formation was quantified by measuring adi-
pocyte-associated Nile Red using fluorometry.Nutrition & Metabolism 2007, 4:22 http://www.nutritionandmetabolism.com/content/4/1/22
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ity depends on the ratio of apoCII/apoCIII expression. A
high ratio of apoCII/apoCIII promotes LPL activity,
whereas a low apoCII/apoCIII ratio inhibits LPL function.
Since this ratio can significantly affect extracellular LPL
activity and in turn fatty acid uptake and storage by adi-
pocytes, we determined apoCII and apoCIII expression
levels in adipocytes treated with or without siRNA for LPL.
Although expression of both regulators was largely unaf-
fected by LPL-siRNA treatment, we did find a small but
reproducible effect on their expression as a result of
diminished LPL expression (Fig. 6B). ApoCII expression
increased by ~20%, while apoCIII expression decreased
by ~20%.
Discussion
The generation of fatty acids from dietary sources and
their uptake by cells are essential processes for efficient
energy metabolism and storage. A general role for LPL in
these processes has been confirmed from LPL gene abla-
tion studies in mice which results in a lethal phenotype
[28]. Naturally occurring LPL gene mutations have also
been reported in the human population that lead to
severe hypertriglyceridemia [37]. However, in light of
these studies which have established a critical systemic
role for LPL in overall fatty acid handling, investigations
carried out to evaluate the direct contributions of adi-
pocyte-specific LPL toward lipid storage have not yielded
conclusive evidence because of compensatory increases in
endogenous fatty acid synthesis [29]. The resulting limita-
tions of published in vivo studies are likely due to hormo-
nal regulation responsible for adipose mass preservation
[29]. To circumvent this problem and obtain direct quan-
titative evidence of the role of adipocyte-derived LPL in
lipid storage, we used a well established in vitro culture
model of adipocyte differentiation [38]. Differentiation of
this culture model to full adipocytes resulted in a 6-fold
increase in LPL mRNA expression. This increase in LPL
mRNA translated into a 2-fold increase in cell surface-
associated LPL enzymatic activity and, importantly, ~10-
fold increase in intracellular lipid storage. Using siRNA
specific for LPL, we were able to reduce LPL expression by
≥ 50% during the course of adipocyte differentiation. This
reduction in adipocyte LPL expression resulted in a paral-
lel decrease in lipid storage of ~80%, which was com-
pletely reversed by the exogenous addition of either
purified LPL or palmitate. These results clearly establish
that adipocyte-derived LPL plays a quantitatively impor-
tant role in intracellular lipid accumulation.
It is now well established that LPL requires apoCII as a co-
factor for efficient triacylglycerol hydrolysis [39,40]. This
fact is highlighted by the observation that mutations in
the apoCII gene lead to abnormally high levels of circulat-
ing triacylglycerols [41]. Following its synthesis and secre-
tion by hepatocytes, apoCII associates with circulating
lipoproteins and stimulates LPL-mediated hydrolysis
once in contact with LPL that is associated with the vascu-
lar wall. ApoCII is a multidomain protein with binding
sites for both LPL and lipid components of circulating
lipoprotein particles [42,43]. The dual binding domains
of apoCII are thought to anchor LPL to the particle surface
while permitting substrate access to its active site [42]. In
contrast, apoCIII is a potent inhibitor of LPL activity
[44,45]. Because of this, the expression levels, or ratio, of
apoCII to apoCIII can be a major influence on extracellu-
lar LPL activity [46]. ApoCII and apoCIII are known to
carry out their functions in the circulation largely while
bound to lipoproteins. In the extravascular environment,
we questioned if other non-hepatic sources, such as adi-
Expression of apoCII and apoCIII in control versus LPL- siRNA-treated adipocytes Figure 6
Expression of apoCII and apoCIII in control versus 
LPL-siRNA-treated adipocytes. (A) 3T3-L1 pre-adi-
pocytes were incubated with induction reagents for 5 days as 
in Fig. 1. Total RNA was isolated from 3T3-L1 adipocytes and 
mouse liver. mRNA was converted to cDNA with reverse 
transcriptase and the sequences for apoCII (147bp) and 
apoCIII (99 bp) were amplified by PCR. Amplification of β-
actin sequence (287 bp) was performed as a loading control. 
(B) 3T3-L1 cells were transfected with LPL-siRNA, followed 
by incubation with adipocyte induction reagents. After five 
days post-induction, total RNA was isolated from adipocytes 
and apoCII and apoCIII expression were assessed by qRT-
PCR. Results were analyzed by the Comparative CT method, 
with fully differentiated, non-treated adipocytes representing 
100% expression. Amplification of β-actin mRNA was per-
formed in parallel and used to normalize replicate points.Nutrition & Metabolism 2007, 4:22 http://www.nutritionandmetabolism.com/content/4/1/22
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pocytes, contribute to expression of apoCII and apoCIII
and in doing so provide their own source of LPL regula-
tors to manage extravascular lipid hydrolysis. This is
indeed the case for differentiated adipocytes as RT-PCR
analysis revealed expression of both apoCII and apoCIII.
We also examined the apoCII/apoCIII expression ratio by
qRT-PCR analysis and found potential regulation of this
ratio in adipocytes that appears to be influenced by LPL
expression levels; decreased LPL expression following
siRNA treatment resulted in a small but reproducible
increase in apoCII and decrease in apoCIII expression.
This change in the apoCII/apoCIII ratio may reflect a com-
pensatory mechanism whereby reduced levels of LPL are
counterbalanced by an increase in the apoCII/apoCIII
ratio. Increasing the apoCII/apoCIII ratio may serve to
ensure more effective activation of the remaining pool of
extracellular LPL.
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